A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

This study is testing an engineered immune cell therapy called C-CAR031 — a type of CAR-T cell treatment — for patients with advanced liver cancer (hepatocellular carcinoma, HCC) that has not responded to previous treatments. The engineered cells are designed to recognize and attack a protein called GPC3 found on liver cancer cells. **You may be eligible if...** - You are between 18 and 75 years old with confirmed liver cancer (Barcelona Stage B or C) - Your cancer has progressed on or after at least one prior standard systemic therapy - You have at least one measurable tumor, and your liver function is adequate (Child-Pugh score 6 or less) - Your blood counts and organ function meet the required minimums - Your tumor is likely to express GPC3 **You may NOT be eligible if...** - You have had a prior liver transplant or any prior cell therapy - The tumor takes up more than 50% of your liver - You have cancer that has spread to the brain or bones - You have moderate to severe fluid buildup in the abdomen (ascites) - You are pregnant or breastfeeding - You have active hepatitis C, syphilis, or significant immune system disease - You have severe heart disease or bleeding risks Talk to your doctor to see if this trial is right for you.